Angion

Angion

Biotechnology, 51 Charles Lindbergh BLVD, Uniondale, New York, 11553, United States, 11-50 Employees

angion.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 51********

Who is ANGION

We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic...

Read More

map
  • 51 Charles Lindbergh BLVD, Uniondale, New York, 11553, United States Headquarters: 51 Charles Lindbergh BLVD, Uniondale, New York, 11553, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • Jay Venkatesan CEO:   Jay Venkatesan

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ANGION

Angion Org Chart and Mapping

Jay Venkatesan

Chief Executive Officer

Employees

Latha Paka

Director, in-Vivo Pharmacology/Pre-Clinical Research

Sunny Loh

Corporate Controller

Tracy Mayne

Vice President, Head of Medical Affairs

Brandy Dupee

Clinical Trial Coordinator

Maureen Curran

Vice President, Pharmacovigilance and Risk Management

Cirkine Sherry

Clinical Trial Coordinator

Stacey Kaufusi

Senior Director, Quality

Gabrielle Scharff

Senior Clinical Trial Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Angion

Answer: Angion's headquarters are located at 51 Charles Lindbergh BLVD, Uniondale, New York, 11553, United States

Answer: Angion's phone number is 51********

Answer: Angion's official website is https://angion.com

Answer: Angion's revenue is $10 Million to $25 Million

Answer: Angion's SIC: 2834

Answer: Angion's NAICS: 561110

Answer: Angion has 11-50 employees

Answer: Angion is in Biotechnology

Answer: Angion contact info: Phone number: 51******** Website: https://angion.com

Answer: We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have limitations.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access